Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.7K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

5.1K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
5.1K
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

776
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
776
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Driving factors in pediatric emergency department use: an ecological retrospective study.

PloS one·2026
Same author

Subcutaneous ivermectin treatment in severe strongyloidiasis: is it time to recommend drug concentration measurements and parasitological stool monitoring follow-up?

Journal of travel medicine·2025
Same author

Exploring reasons and motivations for suicide attempts in prison before and during the SARS-CoV-2 pandemic.

Health & justice·2025
Same author

Pain medication associated with decreased physical performance and rehabilitation progress.

Pain reports·2025
Same author

The Hyperkinetic Circulatory Response during Exercise in Metabolic Myopathies: A Peculiar Model of Integrated Biology.

Medicine and science in sports and exercise·2025
Same author

Antipsychotic medication for behaviors that challenge in individuals with intellectual disabilities: a clinically informed review.

Frontiers in psychiatry·2025

Related Experiment Video

Updated: Apr 21, 2026

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.0K

Reversible ventricular arrythmia induced by dasatinib.

Hervé Spechbach1, Philippe Morel1, Kuntheavy Ing Lorenzini2

  • 1Department of Internal Medicine, University of Geneva Hospitals Geneva, Switzerland.

Clinical Case Reports
|October 31, 2014
PubMed
Summary

Ventricular arrhythmias are rare but serious side effects of dasatinib, a tyrosine kinase inhibitor. Regular electrocardiogram (ECG) monitoring is crucial for chronic myeloid leukemia patients undergoing this treatment.

Keywords:
Adverse drug reactionBCR-ABL (breakpoint cluster region-abelson)chronic myeloid leukaemiadasatinibventricular arrhythmia

More Related Videos

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

7.8K
Modifications of the Langendorff Method for Simultaneous Isolation of Atrial and Ventricular Myocytes from Adult Mice
06:27

Modifications of the Langendorff Method for Simultaneous Isolation of Atrial and Ventricular Myocytes from Adult Mice

Published on: May 13, 2021

5.7K

Related Experiment Videos

Last Updated: Apr 21, 2026

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.0K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

7.8K
Modifications of the Langendorff Method for Simultaneous Isolation of Atrial and Ventricular Myocytes from Adult Mice
06:27

Modifications of the Langendorff Method for Simultaneous Isolation of Atrial and Ventricular Myocytes from Adult Mice

Published on: May 13, 2021

5.7K

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Dasatinib is a tyrosine kinase inhibitor used in chronic myeloid leukemia treatment.
  • While effective, dasatinib can cause rare but severe cardiac complications.
  • Ventricular arrhythmias represent a significant potential adverse event.

Purpose of the Study:

  • To highlight the rare risk of dasatinib-induced ventricular arrhythmias.
  • To emphasize the importance of physician awareness regarding this complication.
  • To recommend regular electrocardiogram (ECG) monitoring during dasatinib therapy.

Main Methods:

  • This is a clinical observation summary.
  • It reviews known adverse events associated with dasatinib.
  • Focuses on the incidence and clinical significance of ventricular arrhythmias.

Main Results:

  • Ventricular arrhythmias are identified as rare but critical adverse events during dasatinib treatment.
  • The study underscores the need for vigilance in monitoring cardiac function.
  • ECG monitoring is presented as a key preventive measure.

Conclusions:

  • Physicians must be aware of the potential for dasatinib to induce ventricular arrhythmias in chronic myeloid leukemia patients.
  • Regular ECG monitoring is essential for early detection and management of cardiac complications.
  • Proactive cardiac surveillance improves patient safety during tyrosine kinase inhibitor therapy.